newsfilter
← Latest News
GlobeNewswire·

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

[212Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date: Four of the initial